Adjuvant effects of Chinese medicinal tonics on gastric, liver, and colorectal cancers-OMICs-based contributions to understanding their mechanism of action.
- 2022-11-29
- Frontiers in pharmacology 13
- Zhigang Zuo
- Jia Jia
- Hongliang Li
- Run Shi
- Di Wang
- Ke-Wu Zeng
- Hong Nie
- Xin-Guo Wang
- Wen Liu
- Minglun Li
- Yibin Feng
- Xuan Bin Wang
- PubMed: 36523499
- DOI: 10.3389/fphar.2022.986765
Study Design
- Type
- Review
- Methods
- Systematic literature search in PubMed, ProQuest, Web of Knowledge, CNKI, Chongqing VIP, and Wanfang from 1 Jan 2011 to 31 May 2022
Gastric, liver, and colorectal cancers belong to gastrointestinal (GI) cancers, one of the most threatening diseases in the world. The tonics class in Chinese medicines plays a critical role in antigastrointestinal cancer as adjuvants. However, it is a challenge to study the effects and underlying mechanisms of tonics due to their multiple components and multiple targets; OMICs were introduced to facilitate the investigation of the complex mixture of tonics. In this review, the online databases PubMed, ProQuest, Web of Knowledge, China National Knowledge Infrastructure (CNKI), Chongqing VIP, and Wanfang were retrieved from 1 January 2011 to 31 May 2022, in an aim to summarize and discuss the research progress of the effects and, especially, the underlying mechanisms of tonics for antigastrointestinal cancers via OMICs. The results showed that through the combination of OMICs and other technologies, tonics have been used for gastrointestinal cancer by targeting cancer hallmarks, enhancing body resistance to carcinogenesis, enhancing therapeutic effects, and/or decreasing side effects. In conclusion, tonics may play a promising role in gastric, liver, and colorectal cancers as adjuvants and can be well investigated via the combination of OMICs and other technologies, which deserves further study.